S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.53 (-0.43%)
AAPL   168.73 (-0.30%)
MSFT   287.47 (-0.58%)
META   177.52 (-0.46%)
GOOGL   119.10 (-0.50%)
AMZN   140.64 (-1.44%)
TSLA   861.95 (-2.39%)
NVDA   179.68 (-0.71%)
NIO   20.83 (+3.89%)
BABA   94.96 (+2.74%)
AMD   98.19 (-0.87%)
MU   62.33 (+1.51%)
T   18.05 (+0.22%)
CGC   3.15 (-4.26%)
GE   78.88 (+2.26%)
F   15.83 (+2.13%)
DIS   117.76 (+4.74%)
AMC   25.43 (+7.44%)
PYPL   99.11 (+0.20%)
PFE   48.32 (-3.26%)
NFLX   242.80 (-0.54%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.53 (-0.43%)
AAPL   168.73 (-0.30%)
MSFT   287.47 (-0.58%)
META   177.52 (-0.46%)
GOOGL   119.10 (-0.50%)
AMZN   140.64 (-1.44%)
TSLA   861.95 (-2.39%)
NVDA   179.68 (-0.71%)
NIO   20.83 (+3.89%)
BABA   94.96 (+2.74%)
AMD   98.19 (-0.87%)
MU   62.33 (+1.51%)
T   18.05 (+0.22%)
CGC   3.15 (-4.26%)
GE   78.88 (+2.26%)
F   15.83 (+2.13%)
DIS   117.76 (+4.74%)
AMC   25.43 (+7.44%)
PYPL   99.11 (+0.20%)
PFE   48.32 (-3.26%)
NFLX   242.80 (-0.54%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.53 (-0.43%)
AAPL   168.73 (-0.30%)
MSFT   287.47 (-0.58%)
META   177.52 (-0.46%)
GOOGL   119.10 (-0.50%)
AMZN   140.64 (-1.44%)
TSLA   861.95 (-2.39%)
NVDA   179.68 (-0.71%)
NIO   20.83 (+3.89%)
BABA   94.96 (+2.74%)
AMD   98.19 (-0.87%)
MU   62.33 (+1.51%)
T   18.05 (+0.22%)
CGC   3.15 (-4.26%)
GE   78.88 (+2.26%)
F   15.83 (+2.13%)
DIS   117.76 (+4.74%)
AMC   25.43 (+7.44%)
PYPL   99.11 (+0.20%)
PFE   48.32 (-3.26%)
NFLX   242.80 (-0.54%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.53 (-0.43%)
AAPL   168.73 (-0.30%)
MSFT   287.47 (-0.58%)
META   177.52 (-0.46%)
GOOGL   119.10 (-0.50%)
AMZN   140.64 (-1.44%)
TSLA   861.95 (-2.39%)
NVDA   179.68 (-0.71%)
NIO   20.83 (+3.89%)
BABA   94.96 (+2.74%)
AMD   98.19 (-0.87%)
MU   62.33 (+1.51%)
T   18.05 (+0.22%)
CGC   3.15 (-4.26%)
GE   78.88 (+2.26%)
F   15.83 (+2.13%)
DIS   117.76 (+4.74%)
AMC   25.43 (+7.44%)
PYPL   99.11 (+0.20%)
PFE   48.32 (-3.26%)
NFLX   242.80 (-0.54%)
NYSE:TEVA

Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

$11.09
-0.11 (-0.98%)
(As of 08/11/2022 03:59 PM ET)
Add
Compare
Today's Range
$11.07
$11.37
50-Day Range
$6.86
$11.20
52-Week Range
$6.78
$11.23
Volume
902,921 shs
Average Volume
18.67 million shs
Market Capitalization
$12.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Teva Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
4.0% Downside
$10.67 Price Target
Short Interest
Healthy
1.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.59 M Sold Last Quarter
Proj. Earnings Growth
0.82%
From $2.43 to $2.45 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars

Medical Sector

1068th out of 1,112 stocks

Pharmaceutical Preparations Industry

524th out of 544 stocks

TEVA stock logo

About Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Teva Pharmaceutical Industries Stock Up 1.8 %

Shares of NYSE:TEVA traded up $0.20 during mid-day trading on Wednesday, reaching $11.20. The company had a trading volume of 15,200,838 shares, compared to its average volume of 10,722,460. Teva Pharmaceutical Industries has a twelve month low of $6.78 and a twelve month high of $11.23. The company has a debt-to-equity ratio of 2.07, a quick ratio of 0.74 and a current ratio of 1.11. The stock has a market capitalization of $12.36 billion, a PE ratio of -11.79, a price-to-earnings-growth ratio of 4.20 and a beta of 1.31. The stock's 50 day moving average is $8.28 and its 200-day moving average is $8.47.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. UBS Group assumed coverage on Teva Pharmaceutical Industries in a research report on Monday, June 13th. They set a "neutral" rating and a $10.00 price objective for the company. Bank of America upgraded Teva Pharmaceutical Industries from a "neutral" rating to a "buy" rating and increased their price objective for the company from $10.00 to $13.00 in a research report on Friday, August 5th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Friday, June 17th. The Goldman Sachs Group boosted their target price on shares of Teva Pharmaceutical Industries from $9.00 to $10.00 and gave the company a "neutral" rating in a research note on Tuesday, August 2nd. Finally, Piper Sandler downgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "underweight" rating and cut their target price for the company from $11.00 to $7.00 in a research note on Wednesday, May 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $10.67.

Insider Transactions at Teva Pharmaceutical Industries

In other news, VP David Matthew Stark sold 58,163 shares of the company's stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $9.04, for a total value of $525,793.52. Following the transaction, the vice president now directly owns 2,974 shares of the company's stock, valued at $26,884.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, VP David Matthew Stark sold 58,163 shares of the company's stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $9.04, for a total value of $525,793.52. Following the completion of the sale, the vice president now directly owns 2,974 shares in the company, valued at $26,884.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Hafrun Fridriksdottir sold 130,000 shares of the company's stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $8.22, for a total transaction of $1,068,600.00. Following the completion of the sale, the vice president now owns 1,387 shares of the company's stock, valued at $11,401.14. The disclosure for this sale can be found here. 0.82% of the stock is currently owned by company insiders.

Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock News Headlines

Volume Surges Spark Turnarounds for These 3 Stocks (TEVA)
There are countless historical chart examples of high volume moves that mark the beginning of sustained rallies or slumps. Let’s tune into a few examples.
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Is This Rare Berkshire Hathaway Miscue Finally a Buy?
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Company Calendar

Last Earnings
10/27/2021
Today
8/11/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
37,537
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
-3.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
8 Analysts

Profitability

Net Income
$417 million
Pretax Margin
-12.47%

Debt

Sales & Book Value

Annual Sales
$15.88 billion
Cash Flow
$3.72 per share
Book Value
$8.91 per share

Miscellaneous

Outstanding Shares
1,103,330,000
Free Float
1,094,283,000
Market Cap
$12.24 billion
Optionable
Optionable
Beta
1.31














TEVA Stock - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price forecast for 2022?

8 Wall Street research analysts have issued twelve-month price objectives for Teva Pharmaceutical Industries' stock. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they anticipate the company's share price to reach $10.67 in the next year. This suggests that the stock has a possible downside of 4.8%.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2022?

Teva Pharmaceutical Industries' stock was trading at $8.01 on January 1st, 2022. Since then, TEVA stock has increased by 40.0% and is now trading at $11.21.
View the best growth stocks for 2022 here
.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our TEVA earnings forecast
.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its quarterly earnings data on Wednesday, October, 27th. The company reported $0.59 earnings per share for the quarter, missing analysts' consensus estimates of $0.65 by $0.06. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $4.05 billion. Teva Pharmaceutical Industries had a negative net margin of 6.83% and a positive trailing twelve-month return on equity of 25.68%. The company's quarterly revenue was down 2.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.56 earnings per share.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $2.40-$2.60 for the period. The company issued revenue guidance of $15.00 billion-$15.60 billion, compared to the consensus revenue estimate of $15.67 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different institutional and retail investors. Top institutional investors include Clal Insurance Enterprises Holdings Ltd (1.72%), Harel Insurance Investments & Financial Services Ltd. (1.04%), Swiss National Bank (0.42%), Van ECK Associates Corp (0.29%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.29%) and Deutsche Bank AG (0.25%). Insiders that own company stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eli Shani, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $11.21.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $12.37 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($0.95) on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

The company employs 37,537 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.

This page (NYSE:TEVA) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.